Amarantus Relocates Headquarters to Janssen Labs @
Post# of 94335
Posted On: 10/30/2013 12:23:49 PM
Amarantus Relocates Headquarters to Janssen Labs @QB3 Incubator in San Francisco
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has moved to Janssen Labs @QB3 in San Francisco. The Company was honored to be selected to join Janssen Labs @QB3 and officially moved into its new space at Janssen Labs on October 28th, 2013.
Janssen Labs @QB3 is a 5,000 square foot space within QB3's 24,000-square foot incubator located at 953 Indiana Street. "The San Francisco Bay Area is home to one of the most diverse and successful biotechnology communities in the world," said Gerald E. Commissiong, President & CEO of Amarantus. "Moving our operations to Janssen Labs @QB3 will add tremendous value to the Company going forward. We will get direct access to key services and mentoring that will allow management to position the Company to significantly increase shareholder value as we move forward."
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3, a 5,000 sq ft satellite site consisting of lab and office space within QB3's newly renovated 24,000 sq ft location at 953 Indiana St., San Francisco, CA. Janssen Labs provides a capital-efficient, resource-rich environment where emerging companies can transform the scientific discoveries of today into the breakthrough healthcare products of tomorrow. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
CONTACT: Investor/Media Contacts
Russell Miller, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408.737.2734 x 109
ir@amarantus.com
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has moved to Janssen Labs @QB3 in San Francisco. The Company was honored to be selected to join Janssen Labs @QB3 and officially moved into its new space at Janssen Labs on October 28th, 2013.
Janssen Labs @QB3 is a 5,000 square foot space within QB3's 24,000-square foot incubator located at 953 Indiana Street. "The San Francisco Bay Area is home to one of the most diverse and successful biotechnology communities in the world," said Gerald E. Commissiong, President & CEO of Amarantus. "Moving our operations to Janssen Labs @QB3 will add tremendous value to the Company going forward. We will get direct access to key services and mentoring that will allow management to position the Company to significantly increase shareholder value as we move forward."
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3, a 5,000 sq ft satellite site consisting of lab and office space within QB3's newly renovated 24,000 sq ft location at 953 Indiana St., San Francisco, CA. Janssen Labs provides a capital-efficient, resource-rich environment where emerging companies can transform the scientific discoveries of today into the breakthrough healthcare products of tomorrow. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
CONTACT: Investor/Media Contacts
Russell Miller, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408.737.2734 x 109
ir@amarantus.com
(0)
(0)